Related Experiment Video
Updated: Apr 6, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
Electro-peroxone treatment of the antidepressant venlafaxine: Operational parameters and mechanism
Xiang Li1, Yujue Wang1, Jian Zhao1
1School of Environment, Beijing Key Laboratory for Emerging Organic Contaminants Control, State Key Joint Laboratory of Environmental Simulation and Pollution Control, Tsinghua University, Beijing 100084, China.
Abstract:
Degradation of the antidepressant venlafaxine by a novel electrocatalytic ozonation process, electro-peroxone (E-peroxone), was studied. The E-peroxone treatment involves sparging ozone generator effluent (O2 and O3 gas mixture) into an electrolysis reactor that is equipped with a carbon-polytetrafluoroethylene cathode to electrocatalytically transform O2 in the bubbled gas to H2O2. The in-situ generate H2O2 then reacts with the bubbled O3 to yield OH, which can non-selectively degrade organic compounds rapidly in the solution. Thanks to the significant OH production, the E-peroxone treatment greatly enhanced both venlafaxine degradation and total organic carbon (TOC) removal as compared to ozonation and electrolysis alone. Under optimal reaction conditions, complete venlafaxine degradation and TOC elimination could be achieved within 3 and 120 min of E-peroxone process, respectively. Based on the by-products (e.g., hydroxylated venlafaxine, phenolics, and carboxylic acids) identified by UPLC-UV and UPLC/Q-TOF-mass spectrometry, plausible reaction pathways were proposed for venlafaxine mineralization by the E-peroxone process. The results of this study suggest that the E-peroxone treatment may provide a promising way to treat venlafaxine contaminated water.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Electroconvulsive Therapy
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

